Estudio Histólogico e Inmunohistoquímico en casos de neoplasias de linfocitos T

Vitae: Academia Biomédica Digital, ISSN 1317-987X, Nº. 12, 200218 pags
Source: OAI

ABSTRACT Aunque habitualmente la histología de los linfomas está bien definida, en el curso del estudio y tipificación fenotípica de los mismos durante varios años, la inmunohistoquímica puede ser imprescindible para realizar un diagnóstico con certeza, pues nos permite no sólo aclarar complejas situaciones, sino también precisar el fenotipo de estas neoplasias y lograr así una clasificación adecuada. Como ya es ampliamente conocido, en el caso de los linfomas, es fundamental conocer el inmunofenotipo, debido a que este es requisito indispensable para decidir el tratamiento a seguir. En este sentido, el presente artículo ilustra los aspectos mencionados al exponer datos clínicos, histopatológicos e inmunohistoquímicos obtenidos de 120 casos de neoplasias de células T.

  • Blood 10/1994; 84(5):1361-92. · 9.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have indicated that some patients with Hodgkin disease have an aggressive clinical course. However, their characteristics have not been elucidated. Six patients initially diagnosed as having Hodgkin disease with subsequent transformation to CD30 positive non-Hodgkin lymphoma were clinically and immunohistochemically studied. Ten patients with classic anaplastic large cell lymphoma (ALCL) and 19 patients with classic Hodgkin disease were studied for comparison by immunohistochemistry. Five patients, excluding one whom the authors recently encountered, had an aggressive clinical course and died within approximately 1 year after diagnosis; four of them were autopsied. Common histologic findings in the six patients included sheets of atypical mononuclear cells and sinusoidal infiltration of small numbers of these cells, as well as Reed-Sternberg cells or lacunar cells. Follow-up biopsies revealed histologic progression to ALCL in which sheets of atypical mononuclear or multinucleated cells spread throughout the lymph nodes. Immunohistochemically, epithelial membrane antigen, granzyme B, perforin, and pancadherin were expressed frequently in the six patients and in ALCL but were not expressed in Hodgkin disease. Latent membrane protein-1 (LMP-1) and Epstein-Barr virus-encoded RNA (EBER-1) were totally negative in the six patients and in ALCL but were expressed frequently in Hodgkin disease. In contrast, LeuM1 (CD15) was expressed frequently in the six patients and in Hodgkin disease, whereas it was not expressed in ALCL. MT1 (CD43), UCHL-1 (CD45RO), and P80 were totally negative in the six patients and in Hodgkin disease, whereas they were expressed variably in ALCL. These results suggest that the six patients studied had intermediate phenotypes between ALCL and Hodgkin disease. The authors also suggest that patients with sheets of atypical mononuclear cells and sinusoidal infiltration of atypical mononuclear and multinucleated cells have an aggressive clinical course and should be treated with intensive chemotherapy.
    Cancer 03/1999; 85(4):970-9. · 5.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Large B-cell lymphoma manifesting in the mediastinum shows distinctive clinical and immunophenotypic features and is recognized as a unique type of large B-cell lymphoma in the Revised European-American Lymphoma classification. Fifty-one cases of primary mediastinal large B-cell lymphoma were retrieved from the immunodiagnosis laboratory database files and were stained with anti-CD30 (Ber-H2). Of the 51 cases, 35 (69%) stained for CD30. This staining ranged from strong membrane staining of all or almost all of the neoplastic cells to positivity of rare individual cells. Eleven cases (22%) were negative; 4 (8%) were equivocal. Only 1 case was uninterpretable owing to B-5 fixation and lack of a positive internal control. Thus, the majority of mediastinal large B-cell lymphomas express the Hodgkin marker CD30. This finding may result in misdiagnosis of large cell lymphoma as Hodgkin disease.
    American Journal of Clinical Pathology 09/1999; 112(2):241-7. · 2.88 Impact Factor


Available from